Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Harnessing spatiotemporal melatonin delivery from engineered platforms for targeted microenvironment remodeling in peripheral neuropathy

Sun M., Fan X., Luo Y., Qin L., Li S., Zhang J.

Narrative Review on Neuroinflammation, published in Mater Today Bio (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Mater Today Bio (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42099996
PMCID
PMC13145392
DOI
10.1016/j.mtbio.2026.103144

Abstract (original English)

Peripheral neuropathy, a leading contributor to global disability, arises from persistent neuroinflammation and oxidative stress that progressively dismantle neural support structures. Notably, its pathophysiology is intricately modulated by circadian rhythms. In this context, the endogenous hormone melatonin offers a compelling therapeutic opportunity, given its capacity to orchestrate protective responses across diverse neural cell types. Despite this potential, clinical translation is severely constrained by its suboptimal pharmacokinetic profile. This limitation creates an imperative for innovative biomaterial-based interventions. This review bridges mechanistic insight with engineering design by detailing strategies to achieve spatiotemporally controlled melatonin release through tailored material composition, structural design, and degradation behavior. For traumatic nerve injuries requiring guided regeneration, we examine the utility of implantable conduits. In addressing diffuse neuropathies, we further propose translating these core design principles toward minimally invasive platforms, including injectable hydrogels, microneedles, nanocarriers, and localized depots. The review culminates in a translational roadmap that outlines critical phases for clinical adoption. These phases encompass platform optimization, formulation standardization, rigorous validation of relea

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research